Tina Rydén‐Bergsten

549 total citations
12 papers, 220 citations indexed

About

Tina Rydén‐Bergsten is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Tina Rydén‐Bergsten has authored 12 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Molecular Biology. Recurrent topics in Tina Rydén‐Bergsten's work include Lipoproteins and Cardiovascular Health (5 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Diabetes Treatment and Management (2 papers). Tina Rydén‐Bergsten is often cited by papers focused on Lipoproteins and Cardiovascular Health (5 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Diabetes Treatment and Management (2 papers). Tina Rydén‐Bergsten collaborates with scholars based in Sweden, United States and Finland. Tina Rydén‐Bergsten's co-authors include Ingela Wiklund, Katarina Halling, Astrid Fletcher, Björn Carlsson, Catarina Nilsson, Dinko Rekić, Susanne Johansson, Maria Leonsson‐Zachrisson, Peter J. Greasley and Bergur V. Stefánsson and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Tina Rydén‐Bergsten

12 papers receiving 208 citations

Peers

Tina Rydén‐Bergsten

CCM

SURGE

EDM

Naveed Younis United Kingdom

Xiangbin Zhong China

Frederick Berro Rivera United States

Margarida Borges Portugal

Gurpreet Johal United States

Keld Per Kjeldsen Italy

Y Henkin Israel

Parminder S Chaggar United Kingdom

Susanne Jung Germany

Juan Cosín‐Aguilar Spain

Naveed Younis United Kingdom

Tina Rydén‐Bergsten

74 ×0.6

CCM

101 ×1.4

SURGE

163 ×2.5

EDM

15 ×0.4

51 ×1.9

Citations per year, relative to Tina Rydén‐Bergsten Tina Rydén‐Bergsten (= 1×) peers Naveed Younis

Countries citing papers authored by Tina Rydén‐Bergsten

Since Specialization

Citations

This map shows the geographic impact of Tina Rydén‐Bergsten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tina Rydén‐Bergsten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tina Rydén‐Bergsten more than expected).

Fields of papers citing papers by Tina Rydén‐Bergsten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tina Rydén‐Bergsten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tina Rydén‐Bergsten. The network helps show where Tina Rydén‐Bergsten may publish in the future.

Co-authorship network of co-authors of Tina Rydén‐Bergsten

This figure shows the co-authorship network connecting the top 25 collaborators of Tina Rydén‐Bergsten. A scholar is included among the top collaborators of Tina Rydén‐Bergsten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tina Rydén‐Bergsten. Tina Rydén‐Bergsten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Rekić, Dinko, Angelica Quartino, Björn Carlsson, et al.. (2024). Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide. British Journal of Clinical Pharmacology. 90(6). 1503–1513. 1 indexed citations

Koren, Michael J., Alexis Hofherr, Jennifer Schumi, et al.. (2022). ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA. Journal of the American College of Cardiology. 79(9). 1475–1475. 14 indexed citations

Nilsson, Catarina, Björn Carlsson, Alexis Hofherr, et al.. (2022). A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II. CPT Pharmacometrics & Systems Pharmacology. 11(12). 1569–1577. 6 indexed citations

Hofherr, Alexis, Jennifer Schumi, Anna Rudvik, et al.. (2022). Abstract 11482: The PCSK9-Targeted Antisense Oligonucleotide AZD8233 Reduces LDL-C, ApoB, and Lp(a) in Patients With Dyslipidemia on Statin Treatment - Data From the Phase 2b ETESIAN Study. Circulation. 146(Suppl_1). 4 indexed citations

Hofherr, Alexis, Jennifer Schumi, Dinko Rekić, et al.. (2022). ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia. Atherosclerosis. 355. 28–28. 6 indexed citations

Rekić, Dinko, Victor Sokolov, Catarina Nilsson, et al.. (2022). AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. British Journal of Clinical Pharmacology. 88(11). 4839–4844. 11 indexed citations

Tyrberg, Björn, Charlotte Wennberg Huldt, Peter Gennemark, et al.. (2020). Inhibition of the prostaglandin D2–GPR44/DP2 axis improves human islet survival and function. Diabetologia. 63(7). 1355–1367. 13 indexed citations

Skrtic, Stanko, Björn Tyrberg, Hans Ericsson, et al.. (2018). Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients. PLoS ONE. 13(12). e0208998–e0208998. 11 indexed citations

Block, Geoffrey A., David P. Rosenbaum, Maria Leonsson‐Zachrisson, et al.. (2016). Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology. 11(9). 1597–1605. 25 indexed citations

10.

Brismar, Kerstin, et al.. (2012). Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: A DIGAMI2 QoL sub-study. Diabetes and Vascular Disease Research. 10(3). 263–269. 7 indexed citations

11.

Wiklund, Ingela, Katarina Halling, & Tina Rydén‐Bergsten. (1999). [What is the effect of lowering the arterial blood pressure on the quality of life? An auxiliary study to the HOT (Hypertension Optimal Treatment) trial].. PubMed. 92(8). 1079–82. 2 indexed citations

12.

Wiklund, Ingela, et al.. (1997). Does Lowering the Blood Pressure Improve the Mood? Quality-of-Life Results from the Hypertension Optimal Treatment (HOT) Study. Blood Pressure. 6(6). 357–364. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact